sandimmun การใช้

• Sandimmun and Neoral, transplant and arthritis drugs, rose 10 percent in local currencies.
• Sandoz said Neoral and its predecessor Sandimmun posted " particularly gratifying increases ."
• Neoral and Sandimmun sales rose 11 percent.
• Sandoz's top-selling drug is Sandimmun, which fights organ rejection after transplants.
• The largest-selling drug was Sandimmun / Neoral, used for transplants which grew 10 percent.
• The new company's best-selling drugs include painkiller Voltaren and organ transplant drugs Sandimmun and Neoral.
• Sales in blockbuster Sandimmun / Neoral, a drug used in transplants, continued to grow, the company said.
• Sales were boosted by a 14 percent rise in sales of Sandimmun and Neoral, organ transplant drugs, Sandoz said.
• Sales in blockbuster Sandimmun / Neoral, a drug used in organ transplants, continued to grow, the company said.
• Pharmaceutical sales at Sandoz, whose flagship drugs include transplant treatments Sandimmun and Neoral, rose 10 percent to 5.8 billion francs.
• Its brands include Gerber and Cibavision, and its major drugs include Diovan for high blood pressure and Sandimmun, used by organ transplant patients.
• The company will be the owner of U . S . babyfood maker Gerber Products Co ., painkiller Voltaren and transplant treatments Sandimmun and Neoral.
• Sandoz's antifungal drug Lamisil added 35 percent, while sales of flagship drugs Sandimmun and Neoral, used in transplant medicine, grew 10 percent.
• The new entity will be the owner of U . S . babyfood maker Gerber Products Co ., painkiller Voltaren and transplant treatments Sandimmun and Neoral.
• Additional agents include ciclosporin ( Neoral / Sandimmun ), letrozole ( Femara ), methylphenidate ( Ritalin ), terbinafine ( Lamisil ), and others.
• Novartis said it now had six drugs with sales of more than 1 billion francs ( $ 600 million ) each, led by transplant drug Sandimmun / Neoral.
• That's after " high sales increases " in such drugs as Sandimmun / Neoral made up for a decline in Voltaren sales after its patent expired.
• Novartis's pharmaceutical revenue is seen rising between s5.6 and 7.6 percent, analysts said, largely driven by Sandoz sales of transplant treatments Neoral and Sandimmun.
• Novartis's pharmaceutical revenue is seen rising between 5.6 and 7.6 percent, analysts said, largely driven by Sandoz sales of transplant treatments Neoral and Sandimmun.
• Sales at Sandoz, which owns U . S . baby food maker Gerber Products Co . and makes the transplant drug Sandimmun, rose 7 percent to 7.87 billion francs.